MA45027B1 - Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations - Google Patents

Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Info

Publication number
MA45027B1
MA45027B1 MA45027A MA45027A MA45027B1 MA 45027 B1 MA45027 B1 MA 45027B1 MA 45027 A MA45027 A MA 45027A MA 45027 A MA45027 A MA 45027A MA 45027 B1 MA45027 B1 MA 45027B1
Authority
MA
Morocco
Prior art keywords
sequence
polynucleotides
polynucleotides encoding
optimized
encoding interleukin
Prior art date
Application number
MA45027A
Other languages
English (en)
Other versions
MA45027A (fr
Inventor
Stephen Hoge
Kerry Benenato
Vladimir Presnyak
Joshua Frederick
Susannah Hewitt
Ailin Bai
Iain Mcfadyen
Ellalahewage Sathyajith Kumarasinghe
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Priority claimed from PCT/US2017/033422 external-priority patent/WO2017201350A1/fr
Publication of MA45027A publication Critical patent/MA45027A/fr
Publication of MA45027B1 publication Critical patent/MA45027B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des polynucléotides comprenant un cadre de lecture ouvert de nucléosides liés codant pour l'interleukine 12 (il-12) humaine, des fragments fonctionnels de ceux-ci, et des protéines de fusion comprenant il-12. Dans certains modes de réalisation, le cadre de lecture ouvert est optimisé en séquence. Dans des modes de réalisation particuliers, l'invention concerne des polynucléotides à séquence optimisée comprenant des nucléotides codant pour la séquence polypeptidique de l'il-12 humaine, ou des séquences ayant une identité de séquence élevée avec ces polynucléotides à séquence optimisée.
MA45027A 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations MA45027B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338483P 2016-05-18 2016-05-18
PCT/US2017/033422 WO2017201350A1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Publications (2)

Publication Number Publication Date
MA45027A MA45027A (fr) 2019-03-27
MA45027B1 true MA45027B1 (fr) 2023-02-28

Family

ID=85793851

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45027A MA45027B1 (fr) 2016-05-18 2017-05-18 Polynucléotides codant pour l'interleukine 12 (il-12) et leurs utilisations

Country Status (1)

Country Link
MA (1) MA45027B1 (fr)

Also Published As

Publication number Publication date
MA45027A (fr) 2019-03-27

Similar Documents

Publication Publication Date Title
MX2022008602A (es) Polinucleotidos que codifican interleucina-12 (il 12) y usos de los mismos.
CO2023004995A2 (es) Proteínas de fusión interleucina-2-fc y métodos de uso
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
MX2022005252A (es) Composiciones de escherichia coli y metodos de las mismas.
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2018231990A3 (fr) Polynucléotides codant pour la méthylmalonyl-coa mutase
ECSP066297A (es) Anticuerpos contra interleucina 22 y usos de los mismos
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
JOP20190009A1 (ar) أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
JOP20210186A1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
EA202190999A1 (ru) Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения
EA202192101A1 (ru) Соединения и их применение
PH12020551492A1 (en) Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP4640282A3 (fr) Protéines et fragments immunodominants dans la sclérose en plaques
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MX2025015568A (es) Receptores quimericos de steap1 y metodos de uso de los mismos
EA202092156A1 (ru) Модифицированные олигонуклеотиды и способы применения в лечении таупатий
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
ZA202202180B (en) Engineered hcv e2 immunogens and related vaccine compositions